Cardiovascular Events Associated with Rofecoxib in a Colorectal Adenoma Chemoprevention Trial
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Selective inhibition of cyclooxygenase-2 (COX-2) may be associated with an increased risk of thrombotic events, but only limited long-term data have been available for analysis. We report on the cardiovascular outcomes associated with the use of the selective COX-2 inhibitor rofecoxib in a long-term, multicenter, randomized, placebo-controlled, double-blind trial designed to determine the effect of three years of treatment with rofecoxib on the risk of recurrent neoplastic polyps of the large bowel in patients with a history of colorectal adenomas. METHODS: A total of 2586 patients with a history of colorectal adenomas underwent randomization: 1287 were assigned to receive 25 mg of rofecoxib daily, and 1299 to receive placebo. All investigator-reported serious adverse events that represented potential thrombotic cardiovascular events were adjudicated in a blinded fashion by an external committee. RESULTS: A total of 46 patients in the rofecoxib group had a confirmed thrombotic event during 3059 patient-years of follow-up (1.50 events per 100 patient-years), as compared with 26 patients in the placebo group during 3327 patient-years of follow-up (0.78 event per 100 patient-years); the corresponding relative risk was 1.92 (95 percent confidence interval, 1.19 to 3.11; P=0.008). The increased relative risk became apparent after 18 months of treatment; during the first 18 months, the event rates were similar in the two groups. The results primarily reflect a greater number of myocardial infarctions and ischemic cerebrovascular events in the rofecoxib group. There was earlier separation (at approximately five months) between groups in the incidence of nonadjudicated investigator-reported congestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the rofecoxib group with the placebo group, 4.61; 95 percent confidence interval, 1.50 to 18.83). Overall and cardiovascular mortality was similar in the two groups. CONCLUSIONS: Among patients with a history of colorectal adenomas, the use of rofecoxib was associated with an increased cardiovascular risk.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib (Section 7.6) is an on-target, mechanism-based class effect.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Rofecoxib, a selective COX-2 inhibitor, was withdrawn from the market in 2004 following the VIGOR and APPROVe trials, which revealed a sustained excess of thrombotic cardiovascular events.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Animal efficacy and short-term human safety data had been reassuring; only long-term cardiovascular outcome trials surfaced the signal.”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mechanism is generally ascribed to disruption of the prostacyclin–thromboxane balance, with COX-2-dependent vascular prostacyclin suppressed, without a compensatory effect on platelet COX-1-dependent thromboxane A2 production [77,78].”
From Beyond Body Weight: A Comprehensive Review of Allometric Scaling in Drug Development for Human Dose Predictions (2026) · cites this paper as [77]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Bombardier, C., Laine, L., Reicin, A., Shapiro, D., Burgos-Vargas, R., Davis, B., Day, R., Ferraz, M. B., Hawkey, C. J., Hochberg, M. C., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200011233432103 · Cited by 4,027
Altman, R., Carreras, L., Díaz, R. S., Figueroa, E. B., Paolasso, E., Parodi, J. C., Cade, J. F., Donnan, G. A., Eadie, M. J., Gavaghan, T. P., et al. (1994) · Cited by 3,322
Antiplatelet Trialists' Collaboration (1994) · BMJ · doi:10.1136/bmj.308.6921.81 · Cited by 3,126
Cardiovascular Risk Associated with Celecoxib in a Clinical Trial for Colorectal Adenoma Prevention
Solomon, S. D., McMurray, J. J. V., Pfeffer, M. A., Wittes, J., Fowler, R., Finn, P., Anderson, W. F., Zauber, A., Hawk, E., & Bertagnolli, M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050405 · Cited by 2,052
The Coxibs, Selective Inhibitors of Cyclooxygenase-2
FitzGerald, G. A., & Patrono, C. (2001) · New England Journal of Medicine · doi:10.1056/nejm200108093450607 · Cited by 1,565
A Randomized Trial of Aspirin to Prevent Colorectal Adenomas
Baron, J. A., Cole, B. F., Sandler, R. S., Haile, R. W., Ahnen, D., Bresalier, R., McKeown-Eyssen, G., Summers, R. W., Rothstein, R., Burke, C. A., et al. (2003) · New England Journal of Medicine · doi:10.1056/nejmoa021735 · Cited by 1,416
Self-citationMcAdam, B. F., Catella-Lawson, F., Mardini, I. A., Kapoor, S., Lawson, J. A., & FitzGerald, G. A. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.1.272 · Cited by 1,305
Complications of the COX-2 Inhibitors Parecoxib and Valdecoxib after Cardiac Surgery
Nussmeier, N. A., Whelton, A. A., Brown, M. T., Langford, R. M., Hoeft, A., Parlow, J. L., Boyce, S. W., & Verburg, K. M. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050330 · Cited by 1,092
Graham, D. J., Campen, D., Hui, R., Spence, M., Cheetham, C., Levy, G., Shoor, S., & Ray, W. A. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17864-7 · Cited by 913
Risk of cardiovascular events and rofecoxib: cumulative meta-analysis
Jüni, P., Nartey, L., Reichenbach, S., Sterchi, R., Dieppe, P. A., & Egger, M. (2004) · The Lancet · doi:10.1016/s0140-6736(04)17514-4 · Cited by 846
Cited by
Items 301–400 of 1,003
NSAIDs and cardiovascular risk
Marsico, F., Paolillo, S., & Filardi, P. P. (2016) · Journal of Cardiovascular Medicine · doi:10.2459/jcm.0000000000000443 · Cited by 121
Chan, F. K. L., Ching, J. Y., Tse, Y. K., Lam, K., Wong, G. L., Ng, S. C., Lee, V. W. Y., Au, K. W., Cheong, P. K., Suen, B. Y., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)30981-9 · Cited by 121
Olsen, A.-M. S., Fosbøl, E. L., Lindhardsen, J., Folke, F., Charlot, M., Selmer, C., Bjerring Olesen, J., Lamberts, M., Ruwald, M. H., Køber, L., et al. (2012) · Circulation · doi:10.1161/circulationaha.112.112607 · Cited by 114
Variability in the Response to Non‐Steroidal Anti‐Inflammatory Drugs: Mechanisms and Perspectives
Bruno, A., Tacconelli, S., & Patrignani, P. (2013) · Basic & Clinical Pharmacology & Toxicology · doi:10.1111/bcpt.12117 · Cited by 115
Cipollone, F., Cicolini, G., & Bucci, M. (2008) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2008.01.002 · Cited by 127
Khumalo, G. P., Wyk, B.-E. V., Feng, Y., & Cock, I. E. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114436 · Cited by 130
Perioperative Intravenous Acetaminophen and NSAIDs
Smith, H. S. (2011) · Pain Medicine · doi:10.1111/j.1526-4637.2011.01141.x · Cited by 116
CD24 Is a New Oncogene, Early at the Multistep Process of Colorectal Cancer Carcinogenesis
Sagiv, E., Memeo, L., Karin, A., Kazanov, D., Jacob–Hirsch, J., MANSUKHANI, M. M., Rechavi, G., Hibshoosh, H. H., & Arber, N. (2006) · Gastroenterology · doi:10.1053/j.gastro.2006.04.028 · Cited by 111
Reckamp, K. L., Krysan, K., Morrow, J. D., Milne, G. L., Newman, R. A., Tucker, C., Elashoff, R. M., Dubinett, S. M., & Figlin, R. A. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0112 · Cited by 117
Scheiman, J. M., & Hindley, C. E. (2010) · Clinical Therapeutics · doi:10.1016/j.clinthera.2010.04.009 · Cited by 119
Critical appraisal of C-reactive protein throughout the spectrum of cardiovascular disease
Osman, R., L'Allier, P. L., Elgharib, N., & Tardif, J.-C. (2006) · Vascular Health and Risk Management · doi:10.2147/vhrm.2006.2.3.221 · Cited by 107
“More recent placebo controlled trials clearly confirmed this toxicity (Bresalier et al 2005; Nussmeier et al 2005; Solomon et al 2005).”
Adventures in vascular biology: a tale of two mediators
Moncada, S. (2006) · Philosophical Transactions of the Royal Society B: Biological Sciences · doi:10.1098/rstb.2005.1775 · Cited by 113
Aging-induced biological changes and cardiovascular diseases.
Fajemiroye, J. O., Cunha, L. C. D., Saavedra-Rodríguez, R., Rodrigues, K. L., Naves, L. M., Mourão, A. A., Silva, E. F. D., Williams, N. E. E., Martins, J. L. R., Sousa, R. B., et al. (2018) · BioMed Research International · doi:10.1155/2018/7156435 · Cited by 109
“However, anti-inflammatory drugs such as Rofecoxib (cyclooxygenase-2 inhibitor), which may trigger cardiovascular problems [135], require a cautious application in patients with CVDs [136].”
BackgroundCurtis, E. M., Fuggle, N. R., Shaw, S., Spooner, L., Ntani, G., Parsons, C. M., Honvo, G., Baird, J., Maggi, S., Dennison, E. M., et al. (2019) · Drugs & Aging · doi:10.1007/s40266-019-00664-x · Cited by 107
Steffel, J., Hermann, M., Greutert, H., Gay, S., Lüscher, T. F., Ruschitzka, F., & Tanner, F. C. (2005) · Circulation · doi:10.1161/01.cir.0000160358.63804.c9 · Cited by 110
An overview of apoptosis and the prevention of colorectal cancer
Watson, A. J. M. (2005) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2005.06.005 · Cited by 120
Molecular Imaging in the Development of Cancer Therapeutics
Czernin, J. G., Weber, W., & Herschman, H. R. (2006) · Annual Review of Medicine · doi:10.1146/annurev.med.57.080904.190431 · Cited by 114
Gastrointestinal and Cardiovascular Risks of Nonsteroidal Anti-inflammatory Drugs
Jones, R. H., Rubin, G. P., Berenbaum, F., & Scheiman, J. M. (2008) · The American Journal of Medicine · doi:10.1016/j.amjmed.2008.01.045 · Cited by 118
Clinical trials with retinoids for breast cancer chemoprevention
Zanardi, S., Serrano, D., Argusti, A., Barile, M., Puntoni, M., & DeCensi, A. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.00938 · Cited by 115
“This finding appears of great relevance in view of the role of COX-2 in breast carcinogenesis (Dannenberg & Subbaramaiah 2003) and of the recent alerts on the risks related to the longterm use of COX-2 inhibitors in chemopreventive trials (Bresalier et al. 2005, Solomon et al. 2005).”
BackgroundCardiovascular and gastrointestinal effects of COX-2 inhibitors and NSAIDs: achieving a balance.
BORER, J. S., & Simon, L. S. (2005) · Arthritis Research & Therapy · doi:10.1186/ar1794 · Cited by 116
Sidiropoulos, P. I., Hatemi, G., Song, I., Avouac, J., Collantes‐Estévez, E., Hamuryudan, V., Herold, M., Kvien, T. K., Mielants, H., Mendoza, J. M., et al. (2008) · Rheumatology · doi:10.1093/rheumatology/kem348 · Cited by 105
Lynch, P. M., Burke, C. A., Phillips, R., Morris, J. S., Slack, R., Wang, X., Liu, J., Patterson, S., Sinicrope, F. A., Rodriguez-Bigas, M. A., et al. (2016) · Gut · doi:10.1136/gutjnl-2014-307235 · Cited by 104
Lanas, Á., & Hunt, R. H. (2006) · Annals of Medicine · doi:10.1080/07853890600925843 · Cited by 109
Abraham, N. S., EL‐SERAG, H. B., Hartman, C. M., Richardson, P., & Deswal, A. M. (2007) · Alimentary Pharmacology & Therapeutics · doi:10.1111/j.1365-2036.2007.03292.x · Cited by 103
The treatment and prevention of knee osteoarthritis: a tool for clinical decision-making
Bliddal, H., & Christensen, R. (2009) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656560903018911 · Cited by 100
“3 COX-2 inhibitors There is overwhelming literature to indicate that long-term use of COX-2 inhibitors is combined with an increased risk of cardiovascular adverse events [64,65].”
BackgroundSolomon, D. H., Glynn, R. J., Rothman, K. J., Schneeweiß, S., Setoguchi, S., Mogun, H., Avorn, J., & Stürmer, T. (2008) · Arthritis Care & Research · doi:10.1002/art.23911 · Cited by 104
Ishikawa, H., Wakabayashi, K., Suzuki, S., Mutoh, M., Hirata, K., Nakamura, T., Takeyama, I., Kawano, A., Gondo, N., Abe, T., et al. (2012) · Cancer Medicine · doi:10.1002/cam4.46 · Cited by 104
Singh, G., Wu, O., Langhorne, P., & Madhok, R. (2006) · Arthritis Research & Therapy · doi:10.1186/ar2047 · Cited by 118
“Introduction One of the most revelatory issues concerning pharmaceuticals in recent years has been the relationship found between selective cyclo-oxygenase (COX)-2 inhibitors and cardiovascular thrombotic adverse events such as acute myocardial infarction (AMI) [1-5].”
BackgroundLanas, Á. (2009) · The American Journal of the Medical Sciences · doi:10.1097/maj.0b013e3181ad8cd3 · Cited by 110
Aspirin and other non-steroidal anti-inflammatory drugs for the prevention of dementia
Jordan, F., Quinn, T. J., McGuinness, B., Passmore, P., Kelly, J. P., Tudur Smith, C., Murphy, K., & Devane, D. (2020) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011459.pub2 · Cited by 60
Joice, M. G., Vasileiadis, G. I., & Amanatullah, D. F. (2018) · The Bone & Joint Journal · doi:10.1302/0301-620x.100b7.bjj-2017-1467.r1 · Cited by 100
COX-2 as a potential biomarker and therapeutic target in melanoma
Tudor, D. V., Bâldea, I., Lupu, M., Kacso, T. P., Kutasi, E., Hopârtean, A., Stretea, R., & Filip, G. A. (2020) · Cancer Biology and Medicine · doi:10.20892/j.issn.2095-3941.2019.0339 · Cited by 105
Opportunities and Strategies for Breast Cancer Prevention Through Risk Reduction
Mahoney, M. C., Bevers, T. B., Linos, E., & Willett, W. C. (2008) · CA A Cancer Journal for Clinicians · doi:10.3322/ca.2008.0016 · Cited by 127
Cyclooxygenase Inhibition in Ischemic Brain Injury
Candelario‐Jalil, E., & Fiebich, B. L. (2008) · Current Pharmaceutical Design · doi:10.2174/138161208784480216 · Cited by 109
Zhang, M., Xu, J., Yao, B., Yin, H., Cai, Q., Shrubsole, M. J., Chen, X., Kon, V., Zheng, W., Pozzi, A., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37398 · Cited by 109
“org Volume 119 Number 4 April 2009 diovascular risk engendered by these agents (8, 26).”
InfluentialThompson, P. A., Ashbeck, E. L., Roe, D. J., Fales, L., Buckmeier, J., Wang, F., Bhattacharyya, A., Hsu, C.-H., Chow, H. H. S., Ahnen, D. J., et al. (2016) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djw152 · Cited by 98
Daniel, C. R., McCullough, M. L., Patel, R. C., Jacobs, E. J., Flanders, W. D., Thun, M. J., & Calle, E. E. (2009) · Cancer Epidemiology, Biomarkers & Prevention · doi:10.1158/1055-9965.epi-08-0750 · Cited by 99
“Despite evidence for cyclooxygenase-2 as a key target in colorectal cancer prevention and promising findings in NSAID intervention trials (28-31, 51), anti-inflammatory drugs are not currently recommended to the general population for the prevention of colorectal cancer due to the potential risk of other adverse healt…”
BackgroundMidgley, R. S., McConkey, C. C., Johnstone, E. C., Dunn, J. A., Smith, J. L., Grumett, S. A., Julier, P., Iveson, C., Yanagisawa, Y., Warren, B., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.6244 · Cited by 99
Ungprasert, P., Srivali, N., Wijarnpreecha, K., Charoenpong, P., & Knight, E. L. (2014) · Rheumatology · doi:10.1093/rheumatology/keu408 · Cited by 98
Ruff, K., Winkler, A., Jackson, R. W., DeVore, D. P., & Ritz, B. W. (2009) · Clinical Rheumatology · doi:10.1007/s10067-009-1173-4 · Cited by 98
“To avoid the cardiac risks [6–9] and gastrointestinal issues [10, 11] associated with traditional OA treatments (particularly with long-term use), many patients have turned to complementary and alternative medicines (CAMs) such as dietary supplements.”
BackgroundSelective COX-2 Inhibitors: Road from Success to Controversy and the Quest for Repurposing
El‐Malah, A., Gineinah, M. M., Deb, P. K., Khayyat, A. N., Bansal, M., Venugopala, K. N., & Aljahdali, A. S. (2022) · Pharmaceuticals · doi:10.3390/ph15070827 · Cited by 106
“A conclusion to the dilemma came only by happenstance, in the Adenomatous Polyp Prevention on Vioxx (APPROVe) study that discovered an increased risk of myocardial infarction and stroke in rofecoxib-treated patients, leading to the premature cessation of the study [30].”
BackgroundCyclooxygenase-2 Selective Nonsteroidal Anti-Inflammatory Drugs and the Risk of Ischemic Stroke
Andersohn, F., Schade, R., Suissa, S., & Garbe, E. (2006) · Stroke · doi:10.1161/01.str.0000226642.55207.94 · Cited by 98
Chemoprevention of Colorectal Neoplasia: The Potential for Personalized Medicine
Arber, N., & Levin, B. (2008) · Gastroenterology · doi:10.1053/j.gastro.2008.02.012 · Cited by 116
Liu, H., Luiten, P. G. M., Eisel, U. L. M., DeJongste, M. J. L., & Schoemaker, R. G. (2013) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2013.02.004 · Cited by 101
Statistical Controversies in Reporting of Clinical Trials
Pocock, S., McMurray, J. J. V., & Collier, T. J. (2015) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2015.10.023 · Cited by 101
Søndergaard, K. B., Weeke, P. E., Wissenberg, M., Olsen, A. S., Fosbøl, E. L., Lippert, F. K., Torp-Pedersen, C. T., Gislason, G., & Folke, F. (2016) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvw041 · Cited by 114
“Several randomized clinical trials found a dose-dependent increased cardiovascular hazard with rofecoxib treatment, which led to a complete withdrawal of rofecoxib from the market in 2004.(3,9,10) Studies on celecoxib have had more ambiguous findings, and although a large randomized clinical trial found a doserelated…”
BackgroundNorwood, S. D., Liao, J., Hammock, B. D., & Yang, G. Y. (2010) · PubMed · Cited by 99
Analgesic strategies beyond the inhibition of cyclooxygenases
Zeilhofer, H. U., & Brune, K. (2006) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2006.07.007 · Cited by 110
O’Donnell, S. C., Cranney, A., Jacobsen, M. J., Graham, I. D., O'Connor, A. M. C., & Tugwell, P. (2006) · Journal of Evaluation in Clinical Practice · doi:10.1111/j.1365-2753.2006.00613.x · Cited by 99
Aggarwal, V., Singla, M., & Kabi, D. (2010) · Journal of Endodontics · doi:10.1016/j.joen.2009.11.010 · Cited by 105
Celecoxib: A Review of its Use in the Management of Arthritis and Acute Pain
Frampton, J. E., & Keating, G. M. (2007) · Drugs · doi:10.2165/00003495-200767160-00008 · Cited by 105
Pruthi, R. S., Derksen, J. E., Moore, D. T., Carson, C. C., Grigson, G., Watkins, C., & Wallen, E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2067 · Cited by 97
Nonsteroidal anti-inflammatory drugs: prostaglandins, indications, and side effects
Pountos, I., Georgouli, T., Bird, H., & Giannoudis, P. (2011) · International Journal of Interferon, Cytokine and Mediator Research · doi:10.2147/ijicmr.s10200 · Cited by 94
“67,68 The APPROVe trial showed a 1.9-fold increase in risk of thrombotic events in patients assigned to the rofecoxib group compared with placebo, whereas the APC trial presented a significant increase in the risk of serious CV events, including CV-related death, myocardial infarction, stroke, and…”
InfluentialINFECTION, INFLAMMATION, AND GASTROINTESTINAL CANCER
Boland, C. R., Luciani, M. G., Gasché, C., & Goel, A. (2005) · Gut · doi:10.1136/gut.2004.060079 · Cited by 108
Association between frequent use of nonsteroidal anti-inflammatory drugs and breast cancer
Rahme, E., Ghosn, J., Dasgupta, K., Rajan, R., & Hudson, M. (2005) · BMC Cancer · doi:10.1186/1471-2407-5-159 · Cited by 96
“In fact, in 2004, two cancer prevention trials [18-20] were terminated prematurely because patients randomized to the COX-2 inhibitor arms experienced more CV events compared to patients given placebo.”
BackgroundAdiponectin circulating levels: A new emerging biomarker of cardiovascular risk
Giannessi, D., Maltinti, M., & Ry, S. D. (2007) · Pharmacological Research · doi:10.1016/j.phrs.2007.09.014 · Cited by 108
A Comparison of the Empirical Performance of Methods for a Risk Identification System
Ryan, P. B., Stang, P., Overhage, J. M., Suchard, M. A., Hartzema, A. G., DuMouchel, W., Reich, C., Schuemie, M. J., & Madigan, D. (2013) · Drug Safety · doi:10.1007/s40264-013-0108-9 · Cited by 99
“It is worth noting that the key evidence supporting these withdrawals was generated from randomized clinical trials and meta-analysis of study results [21–23], though several groups have tried to illustrate retrospectively that these effects could have been detected using observational healthcare database [24–29].”
BackgroundFioravanti, A., Bacaro, G., Giannitti, C., Tenti, S., Cheleschi, S., Guidelli, G. M., Pascarelli, N. A., & Galeazzi, M. (2014) · International Journal of Biometeorology · doi:10.1007/s00484-014-0943-0 · Cited by 95
Schönthal, A. H., Chen, T. C., Hofman, F. M., Louie, S. G., & Petasis, N. A. (2008) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.17.2.197 · Cited by 95
“These adverse effects associated with coxibs appear to be a ‘ class effect ’ that emerges during long-term usage and at elevated dosages [76,77,89-91] – which represent parameters that are highly relevant to their intended chemopreventive or therapeutic anticancer application.”
BackgroundGastrointestinal and Cardiovascular Risk of NonsteroidalAnti-inflammatory Drugs
Al-Saeed, A. H. (2011) · Oman Medical Journal · doi:10.5001/omj.2011.101 · Cited by 100
Risks and Benefits of Celecoxib to Prevent Recurrent Adenomas
Psaty, B. M., & Potter, J. D. (2006) · New England Journal of Medicine · doi:10.1056/nejme068158 · Cited by 95
Amer, M., Bead, V. R., Bathon, J. M., Blumenthal, R. S., & Edwards, D. N. (2010) · Cardiology in Review · doi:10.1097/crd.0b013e3181ce1521 · Cited by 113
Clinical Practice Guideline: Opioid Prescribing for Analgesia After Common Otolaryngology Operations
Anne, S., Mims, J. “., Tunkel, D. E., Rosenfeld, R. M., Boisoneau, D. S., Brenner, M. J., Cramer, J. D., Dickerson, D. M., Finestone, S. A., Folbe, A. J., et al. (2021) · Otolaryngology · doi:10.1177/0194599821996297 · Cited by 109
“In 2005 the COX-2 inhibitor rofecoxib (Vioxx) was removed from the US market after studies showed an increased risk of cardiovascular thrombotic events, including myocardial infarction and stroke.(140,141) Celecoxib was allowed to stay on the market with warnings about the increased cardiovascular risk.”
BackgroundCyclooxygenase: Past, present and future. A tribute to John R. Vane (1927–2004)
Botting, R. M. (2006) · Journal of Thermal Biology · doi:10.1016/j.jtherbio.2005.11.008 · Cited by 118
Short- and Long-Term Effects of Spa Therapy in Knee Osteoarthritis
Fioravanti, A., Iacoponi, F., Bellisai, B., Cantarini, L., & Galeazzi, M. (2010) · American Journal of Physical Medicine & Rehabilitation · doi:10.1097/phm.0b013e3181c1eb81 · Cited by 94
“However, the use of NSAIDs is limited by their negative side effects on the gastrointestinal tract,(3) and the use of COX-2 inhibitors is characterized by an increase in cardiovascular side effects.(4) Acetaminophen is better tolerated compared with NSAIDs and COX-2 inhibitors but does not always provide adequate pain…”
BackgroundMeta-analysis: Methods, strengths, weaknesses, and political uses
Noble, J. H. (2006) · Journal of Laboratory and Clinical Medicine · doi:10.1016/j.lab.2005.08.006 · Cited by 100
Goodson, N. J., Brookhart, A. M., Symmons, D. P. M., Silman, A. J., & Solomon, D. H. (2009) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2007.076760 · Cited by 93
Scott, P. A., Kingsley, G. H., Smith, C. M., Choy, E., & Scott, D. L. (2007) · Annals of the Rheumatic Diseases · doi:10.1136/ard.2006.068650 · Cited by 104
Collaborative, S., Chapman, S. J., Glasbey, J. C., Kelly, M. E., Khatri, C., Nepogodiev, D., Fitzgerald, J. E. F., Bhangu, A. A., Bhangu, A. A., Harrison, E. M., et al. (2014) · British journal of surgery · doi:10.1002/bjs.9614 · Cited by 102
Stroke risk and NSAIDs: a systematic review of observational studies
Varas‐Lorenzo, C., Riera‐Guàrdia, N., Calingaert, B., Castellsagué, J., Pariente, A., Scotti, L., Sturkenboom, M., & Perez‐Gutthann, S. (2011) · Pharmacoepidemiology and Drug Safety · doi:10.1002/pds.2227 · Cited by 105
“The Adenomatous Polyp Prevention on Vioxx trial found a risk of ischemic stroke for rofecoxib twice that for placebo.(2) A meta-analysis of randomized clinical trials reported a moderately increased risk of vascular events associated with selective COX-2 inhibitors, largely attributable to a twofold increased risk of…”
BackgroundTannenbaum, H., Bombardier, C., Davis, P. J., & Russell, A. S. (2006) · PubMed · Cited by 92
White, P. F., Sacan, O., Tufanogullari, B., Eng, M. R., Nuangchamnong, N., & Ogunnaike, B. O. (2007) · Canadian Journal of Anesthesia/Journal canadien d anesthésie · doi:10.1007/bf03022655 · Cited by 100
Molecular markers and targets for colorectal cancer prevention
Janakiram, N. B., & Rao, C. V. (2008) · Acta Pharmacologica Sinica · doi:10.1111/j.1745-7254.2008.00742.x · Cited by 94
Combination regimen with statins and NSAIDs: A promising strategy for cancer chemoprevention
Xiao, H., & Yang, C. S. (2008) · International Journal of Cancer · doi:10.1002/ijc.23718 · Cited by 92
“increased cardiovascular toxicity observed in a trial designed to test the efficacy of rofecoxib to prevent recurrence of colonic polyps.(42) Consequently, recruitment for another trial with rofecoxib was stopped before the final efficacy results were obtained.”
BackgroundMicrosomal Prostaglandin E 2 Synthase-1 Modulates the Response to Vascular Injury
Wang, M., Ihida‐Stansbury, K., Kothapalli, D., Tamby, M. C., Zhou, Y., Chen, L., Grant, G. R., Cheng, Y., Lawson, J. A., Assoian, R. K., et al. (2011) · Circulation · doi:10.1161/circulationaha.110.973685 · Cited by 92
Aljadhey, H. S., Tu, W., Hansen, R. A., Blalock, S. J., Brater, D. C., & Murray, M. D. (2012) · BMC Cardiovascular Disorders · doi:10.1186/1471-2261-12-93 · Cited by 105
Rahme, E., & Nedjar, H. (2007) · Rheumatology · doi:10.1093/rheumatology/kel428 · Cited by 92
NSAIDs, coxibs, CINOD and H2S-releasing NSAIDs: What lies beyond the horizon
Fiorucci, S., Santucci, L., & Distrutti, E. (2007) · Digestive and Liver Disease · doi:10.1016/j.dld.2007.09.001 · Cited by 92
Back, M., Yin, L., & Ingelsson, E. (2012) · European Heart Journal · doi:10.1093/eurheartj/ehr421 · Cited by 90
“Several randomized controlled trials (RCTs) of longterm use of selective coxibs indicated an increased risk of myocardial infarction, stroke, and heart failure compared with either other NSAIDs(1) or placebo.(2) –4 Subsequent meta-analyses(5,6) and registry studies 10 extended those findings and also raised a notion o…”
BackgroundMalmström, R. E., Godman, B., Diogène, E., Baumgärtel, C., Bennie, M., Bishop, I., Brzezinska, A., Bucsics, A., Campbell, S., Ferrario, A., et al. (2013) · Frontiers in Pharmacology · doi:10.3389/fphar.2013.00039 · Cited by 98
“Whilst this reduces gastrointestinal (GI) side-effects, this also reduced the cardioprotective effect of COX-I inhibitors that is similar to low-dose aspirin (Davies and Jamali, 2004; Bresalier et al., 2005).”
BackgroundInfluentialChemoprevention of colorectal cancer: Past, present, and future
Umezawa, S., Higurashi, T., Komiya, Y., Arimoto, J., Horita, N., Kaneko, T., Iwasaki, M., Nakagama, H., & Nakajima, A. (2019) · Cancer Science · doi:10.1111/cas.14149 · Cited by 98
Cancer Chemoprevention by Cyclooxygenase 2 (COX-2) Blockade: Results of case control studies
Harris, R. E., Beebe-Donk, J., & Alshafie, G. A. (2007) · Sub-cellular biochemistry/Subcellular biochemistry · doi:10.1007/1-4020-5688-5_9 · Cited by 100
“Extraordinary media coverage has been given to the two RCTs wherein increases were observed in the risk of adverse cardiovascular outcomes with long term intake of well-known selective COX-2-inhibiting agents (rofecoxib and celecoxib) [99, 100, 101].”
BackgroundBerner, E. S., Houston, T. K., Ray, M. N., Allison, J. J., Heudebert, G. R., Chatham, W. W., Kennedy, J. I., Glandon, G. L., Norton, P. A., Crawford, M. A., et al. (2006) · Journal of the American Medical Informatics Association · doi:10.1197/jamia.m1961 · Cited by 91
Vinogradova, Y., Hippisley‐Cox, J., Coupland, C. A. C., & Logan, R. F. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.05.023 · Cited by 91
Schneeweiss, S., Solomon, D. H., Wang, P. S., Rassen, J., & Brookhart, M. A. (2006) · Arthritis & Rheumatism · doi:10.1002/art.22219 · Cited by 93
Selective cyclooxygenase 2 inhibitors and cardiovascular events
Solomon, D. H. (2005) · Arthritis & Rheumatism · doi:10.1002/art.21132 · Cited by 98
Sethi, R., Gómez‐Coronado, N., Walker, A. J., Robertson, O. D., Agustini, B., Berk, M., & Dodd, S. (2019) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2019.00605 · Cited by 99
Prevention of Bladder Cancer: A Review
Leppert, J. T., Shvarts, O., Kawaoka, K., Lieberman, R., Belldegrun, A. S., & Pantuck, A. J. (2005) · European Urology · doi:10.1016/j.eururo.2005.12.011 · Cited by 90
“Long term exposure to COX-2 inhibitors has been linked with a small but significant increase in cardiovascular events, tempering interest in these agents in thechemopreventionofbladdercancer [72].”
BackgroundPyrko, P., Soriano, N., Kardosh, A., Liu, Y., Uddin, J., Petasis, N. A., Hofman, F. M., Chen, C., Chen, T. C., & Schönthal, A. H. (2006) · Molecular Cancer · doi:10.1186/1476-4598-5-19 · Cited by 100
Perioperative Medication Management for the Patient With Rheumatoid Arthritis
Howe, C. R., Gardner, G. C., & Kadel, N. J. (2006) · Journal of the American Academy of Orthopaedic Surgeons · doi:10.5435/00124635-200609000-00004 · Cited by 96
Ramey, D. R., Watson, D. J., Yu, C., Bolognese, J. A., Curtis, S., & Reicin, A. S. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x43686 · Cited by 90
Self-citationEP2 and EP4 Receptors Regulate Aromatase Expression in Human Adipocytes and Breast Cancer Cells
Subbaramaiah, K., Hudis, C. A., Chang, S.-H., Hla, T., & Dannenberg, A. J. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m705409200 · Cited by 96
RetractedFadaly, W. A. A., Elshaier, Y. A. M. M., Hassanein, E. H. M., & Abdellatif, K. R. A. (2020) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2020.103752 · Cited by 92
Summing the risk of NSAID therapy
Scheiman, J. M., & Fendrick, A. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60722-3 · Cited by 94
Gómez‐Hernández, A., Martín-Ventura, J. L., Sánchez-Galán, E., Vidal, C., Ortego, M., Blanco‐Colio, L. M., Ortega, L. M., Tuñón, J., & Egido, J. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2005.08.035 · Cited by 98
Structural investigation on the selective COX-2 inhibitors mediated cardiotoxicity: A review
Arora, M., Choudhary, S., Singh, P. K., Sapra, B., & Silakari, O. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.117631 · Cited by 93
Polypharmacy in Older Adults With Hypertension: A Comprehensive Review
Mukete, B. N., & Ferdinand, K. C. (2015) · Journal of Clinical Hypertension · doi:10.1111/jch.12624 · Cited by 96
“acetaminophen has been the preferred analgesic used in patients with increased CV risk and hypertension.(31,33) Nevertheless, acetaminophen may elevate BP.”
BackgroundUpdate on cyclooxygenase inhibitors: has a third COX isoform entered the fray?
Hersh, E. V., Lally, E. T., & Moore, P. A. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x56367 · Cited by 102
Fecker, L. F., Stockfleth, E., Nindl, I., Ulrich, C., Forschner, T., & Eberle, J. (2007) · British Journal of Dermatology · doi:10.1111/j.1365-2133.2007.07856.x · Cited by 88
mPGES-1 as a target for cancer suppression
Nakanishi, M., Gokhale, V. M., Meuillet, E. J., & Rosenberg, D. W. (2010) · Biochimie · doi:10.1016/j.biochi.2010.02.006 · Cited by 87
“For example, the cardiovascular events associated with rofecoxib treatment in the adenoma prevention trial (APPROVe) have been well documented [12,46].”
Background
Metadata
- Authors
- Bresalier, R. S., Sandler, R. S., Quan, H., Bolognese, J. A., Oxenius, B., Horgan, K., Lines, C., Riddell, R., Morton, D., Lanas, A., Konstam, M. A., & Baron, J. A.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- University of North Carolina at Chapel Hill (US)
- Mount Sinai Hospital (CA)
- University of Birmingham (GB)
- Tufts Medical Center (US)
- Dartmouth College (US)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2005-03-17
- Volume
- 352
- Issue
- 11
- Pages
- 1092-1102
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2158131645
- Cited by
- 2,519
- References
- 34
- Citations by year
- 2026: 32 · 2025: 25 · 2024: 17 · 2023: 50 · 2022: 48 · 2021: 37 · 2020: 52 · 2019: 56 · 2018: 63 · 2017: 67 · 2016: 85 · 2015: 107 · 2014: 110 · 2013: 117 · 2012: 120
- FWCI
- 219.42
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- University of Birmingham Research Portal (University of Birmingham) (submittedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Health Sciences › Medicine › Oncology › Colorectal Cancer Screening and Detection
- Keywords
- rofecoxib, cardiovascular adverse events, thrombotic complications, COX-2 inhibitors, colorectal adenoma, colorectal cancer chemoprevention, myocardial infarction, cerebral ischemic events, congestive heart failure, pulmonary edema, cardiovascular mortality
- MeSH terms
- Adult, Aged, Aged, 80 and over, Anti-Inflammatory Agents, Non-Steroidal, Aspirin, Cardiovascular Diseases, Double-Blind Method, Female, Humans, Lactones, Male, Middle Aged, Risk, Sulfones, Thrombosis, Colorectal Neoplasms, Incidence, Proportional Hazards Models, Single-Blind Method, Cyclooxygenase Inhibitors, Adenomatous Polyps, Secondary Prevention
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.